Diabetes Mellitus,Inflammation,Obesity: Proposed Treatment Pathways for Current and Future Therapies

World Health Organization. Diabetes: what is diabetes? www.who.int/mediacentre/factsheets/fs312/en/ (accessed 2009 Sept 30).

American Diabetes Association. Economic costs of diabetes in the US in 2007. Diabetes Care 2008; 31: 1–20.

Mao X. , Hong J.Y. , Dong L.Q. . The adiponectin signaling pathways as a novel pharmacological target. Mini Rev Med Chem 2006; 6: 1331–40.

Beltowski J. , Jamroz-Wisniewska A. , Widomska S. Adiponectin and its role in cardiovascular diseases. Cardiovasc Hematol Disord Drug Targets 2008; 8: 7–46.

Karbowska J. , Kochan Z. Role of adiponectin in the regulation of carbohydrate and lipid metabolism. J Physiol Pharmacol 2006; 57: 103–13.

Nishida M. , Funahashi T. , Shimomura I. Pathophysiological significance of adiponectin. Med Mol Morphol 2007; 40: 55–67.

Scherer P.E. , Williams S. , Fogliano M. A novel serum protein similar to Clq, produced exclusively in adipocytes. J Biol Chem 1995; 270: 26746–9.

Maeda K. , Oubo K. , Shimomura I. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM 1 (adipose most abundant gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286–9.

Hu E. , Liang P. , Spiegelman B.M. . AdipoQ is a novel adipose-specific gene disregulated in obesity. J Biol Chem 1996; 271: 10697–703.

Nakano Y. , Tobe T. , Choi-Miura N.H. Isolation and characterization of GBP28, a novel gelatin binding protein purified from human plasma. J Biochem (Tokyo) 1996; 120: 803–12.

Berg A.H. , Combs T.P. , Scherer P.E. . ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002; 13: 84–9.

Giannessi D. , Maltinti M. , Del Ry S. Adiponectin circulating levels: a new emerging biomarker of cardiovascular risk. Pharmacol Res 2007; 56: 459–67.

Ebinuma H. , Miyazaki O. , Yago H. A novel ELISA system for selective measurement of human adiponectin multimers by using proteases. Clin Chim Acta 2006; 372: 47–53.

Hug C. , Wang J. , Ahmad N.S. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA 2004; 101: 10308–13.

Takeuchi T. , Adachi Y. , Ohtsuki Y. Adiponectin receptors, with special focus on the role of the third receptor, T-cadherin, in vascular disease. Med Mol Morphol 2007; 40: 115–20.

Yamauchi T. , Kamon J. , Minokoshi Y. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288–95.

Tomas E. , Tsao T.S. , Saha A.K. Enhanced muscle fat oxidation and glucose transport by ARCP30 globular domain: acetyl-coA carboxylation inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci 2002; 99: 16309–13.

Gable D. , Hurel S. , Humphries S. Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease. Atherosclerosis 2006; 188: 231–44.

Maeda N. , Takahashi M. , Funahashi T. Pparγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094–9.

Kumada M. , Kiahara S. , Ouchi N. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004; 109: 2046–9.

Wolf A.M. , Wolf D. , Rumpold H. Adiponectin induces the anti-inflammatory cytokines lL-10 and IL-IRA in human leukocytes. Biochem Biophys Res Commun 2004; 323: 630–5.

Ouchi N. , Kihara S. , Arita Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473–6.

Arita Y. , Kihara S. , Ouchi N. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002; 105: 2893–8.

Ouchi N. , Kihara S. , Arita Y. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103: 1057–63.

Xu A. , Wang Y. , Keshaw H. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91–100.

Lopez-Bermejo A. , Botas P. , Funahashi T. Adiponectin, hepatocellular dysfunction and insulin sensitivity. Clin Endocrinol (Oxf) 2004; 60: 256–63.

Hui J.M. , Hodge A. , Farrell G.C. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40: 46–54.

Kaser S. , Moschen A. , Cayon A. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005; 54: 117–21.

Kato H. , Kashiwagi H. , Shiraga M. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol 2006; 26: 224–30.

Okamoto Y. , Kihara S. , Ouchi N. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002; 106: 2767–70.

Pischon T. , Girman C.J. , Hotamisligil G.S. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730–7.

Efstathiou S.P. , Tsioulos D.I. , Tsiakou A.G. Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. Stroke 2005; 36: 1915–9.

Kumada M. , Kihara S. , Sumitsuki S. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85–9.

Chen M.P. , Tsai J.C.R. , Chung F.M. Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol 2005; 25: 821–6.

Kawano T. , Saito T. , Yasu T. Close association of hypoadiponectinemia with arteriosclerosis obliterans and ischemic heart disease. Metab Clin Exp 2005; 54: 653–6.

Ohashi K. , Ouchi N. , Kihara S. Adiponectin 1164T mutation is associated with the metabolic syndrome and coronary artery disease. J Am Coll Cardiol 2004; 43: 1195–200.

Hotta K. , Funahashi T. , Arita Y. Plasma concentrations of a novel, adipose specific protein adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595–9.

Hotta K. , Funahashi T. , Bodkin N.L. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001; 50: 1126–33.

Yatagi T. , Nagasaki S. , Taniguchi A. Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism 2003; 50: 1274–9.

Daimon M. , Oizumi T. , Saitoh T. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study. Diabetes Care 2003; 26: 2015–20.

Snehalatha C. , Mukesh B. , Simon M. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian indians. Diabetes Care 2003; 26: 3226–9.

Lindsay R.S. , Funahashi T. , Hanson R.L. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360: 57–8.

Krakoff J. , Funahashi T. , Stehouwer C.D. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003; 26: 1745–51.

Ciasen R. , Schupp M. , Foryst-Ludwig A. PPAR-γ–activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005; 46: 137–43.

Negro R. , Formoso G. , Hassan H. The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. J Endocrinol Invest 2006; 29: 957–61.

Delles C. , Raff U. , Mimran A. Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes. Am J Hypertens 2008; 21: 1330–6.

Inukai K. , Watanabe M. , Nakashima Y. Glimepiride enhances intrinsic peroxisome proliferator-activated receptor-gamma activity in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2005; 328: 484–90.

Araki T. , Emoto M. , Konishi T. Glimepiride increases high-density lipoprotein cholesterol via increasing adiponectin levels in type 2 diabetes mellitus. Metabolism 2009; 58: 143–8.

Tsunekawa T. , Hayashi T. , Suzuki Y. Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. Diabetes Care 2003; 26: 285–9.

Nagasaka S. , Taniguchi A. , Aiso Y. Effect of glimepiride on serum adiponectin level in subjects with type 2 diabetes. Diabetes Care 2003; 26: 2215–6.

Pfützner A. , Marx N. , Lubben G. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results of the pioneer study. J Am Coll Cardiol 2005; 45: 1925–31.

Yu J. , Javorschi S. , Hevener A. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese and type 2 diabetic subjects. Diabetes 2002; 51: 2968–74.

Yang W. , Jeng C. , Wu T. Synthetic peroxisone proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002; 25: 376–80.

Olefsky J. , Saltiel A. PPAR gamma and the treatment of insulin resistance. Trends Endocrinol Metab 2000; 11: 362–8.

Tsuchida A. , Yamauchi T. , Ito Y. Insulin/Foxol pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 2004; 279: 30817–22.

Poitras P. , Tomasetto C. The potential of ghrelin as a prokinetic. Regulatory Peptides 2009; 155: 24–7.

Levin F. , Edholm T. , Schmidt P.T. Ghrelin stimulates gastric emptying and hunger in normal-weight humans. J Clin Endocrinol Metab 2006; 91: 3296–302.

Cummings D.E. , Shannon M.H. . Roles for ghrelin in the regulation of appetite and body weight. Arch Surg 2003; 138: 389–96.

Sun Y. , Asnicar M. , Smith R.G. . Central and peripheral roles of ghrelin on glucose homeostasis. Neuroendocrinology 2007; 86: 215–28.

Ukkola O. Ghrelin and metabolic disorders. Curr Protein Peptide Sci 2009; 10: 2–7.

De Smet B. , Mitselos A. , Depoortere I. Motilin and ghrelin as prokinetic drug targets. Pharmacol Ther 2009; 123: 207–23.

Pusztai P. , Sarman B. , Ruzicska E. Ghrelin: a new peptide regulating the neurohormonal system, energy homeostasis and glucose metabolism. Diab Metab Res Rev 2008; 24: 343–52.

Depoortere I. Targeting the ghrelin receptor to regulate food intake. Regulatory Peptides 2009; 156: 13–23.

Binn M. , Albert C. , Gougeon A. Ghrelin gastrokinetic action in patients with neurogenic gastroparesis. Peptides 2006; 27: 1603–6.

Tack J. , Depoortere I. , Bisschops C. Influence of ghrelin on interdigestive gastrointestinal motility in humans. Gut 2006; 55: 327–33.

Langenberg C. , Bergstrom J. , Laughlin G.A. Ghrelin and the metabolic syndrome in older adults. J Clin Endocrinol Metab 2005; 90: 6448–53.

Dezaki K. , Sone H. , Yada T. Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis. Pharmacol Ther 2008; 118: 239–49.

Katergari S.A. , Milousis A. , Pagonopoulou O. Ghrelin in pathological conditions. Endocrine J 2008; 55: 439–53.

Ueno H. , Shiiya T. , Mizuta M. Plasma ghrelin concentrations in different clinical stages of diabetic complications and glycemic control in Japanese diabetics. Endocrine J 2007; 54: 895–902.

Ishii S. , Kamegai J. , Tamura H. Role of ghrelin in streptozotocin-induced diabetic hyperphagia. Endocrinology 2002; 143: 4934–7.

Gelling R.W. , Overduin J. , Morrison C.D. Effect of uncontrolled diabetes on plasma ghrelin concentrations and ghrelin-induced feeding. Endocrinology 2004; 145: 4575–82.

Dong J. , Peeters T.L. , De Smet B. Role of endogenous ghrelin in the hyperphagia of mice with streptozotocin-induced diabetes. Endocrinology 2006; 147: 2634–42.

Celi F. , Bini V. , Papi F. Circulating acylated and total ghrelin and galanin in children with insulin-treated type 1 diabetes: relationship to insulin therapy, metabolic control and pubertal development. Clin Endocrinol (Oxf) 2005; 63: 139–45.

Kamiji M.M. , Inui A. The role of ghrelin and ghrelin analogues in wasting disease. Curr Opin Clin Nutr Metab Care 2008; 11: 443–51.

Esler W.P. , Rudolph J. , Clause T.H. Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology 2007; 148: 5175–85.

Tack J. , Depoortere I. , Bisschops R. Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Aliment Pharmacol Ther 2005; 22: 847–53.

Murray C.D.R. , Martin N.M. , Patterson M. Ghrelin enhanced gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut 2005; 54: 1693–8.

Qiu W.C. , Wang Z.G. , Wang W.G. Ghrelin improves delayed gastrointestinal transit in alloxan-induced diabetic mice. World J Gastroenterol 2008; 14: 2572–7.

Charoenthongtrakul S. , Giuliana D. , Longo K.A. Enhanced gastrointestinal motility with orally active ghrelin receptor agonists. J Pharmacol Exp Ther 2009; 329: 1178–86.

Shafton A.D. , Sanger G.I. , Witherington I. Oral administration of a centrally acting ghrelin receptor agonist to conscious rats triggers defecation. Neurogastrenterol Motil 2009; 21: 71–7.

Lasseter K.C. , Shaughnessy L. , Cummings D. Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol 2008; 48: 193–202.

Ejskjaer N. , Vestergaard E.T. , Hellstrom P.M. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment Pharmacol Ther 2009; 29: 1179–87.

Fremont L. Biological effects of resveratrol. Life Sci 2000; 66: 663–73.

Mann C.D. , Neal C.P. , Garcea G. Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis. Eur J Cancer Prev 2009; 18: 13–25. DOI 10.1097/CEJ.0b013e3282f0c090

Pillarisetti S. A review of Sirt1 and Sirt1 modulators in cardiovascular and metabolic diseases. Recent Pat Cardiovasc Drug Discov 2008; 3: 156–64.

Haigis M.C. , Guarente L.P. . Mammalian sirtuins—emerging roles in physiology, aging, and calorie restriction. Genes Dev 2006; 20: 2913–21. DOI 10.1101/gad.1467506

Kaeberlein M. , McVey M. , Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev 1999; 13: 2570–8.

Borra M.T. , Smith B.C. , Denu J.M. . Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 2005; 280: 17187–95. DOI 10.1074/jbc.M501250200

Kitamura Y.I. , Kitamura T. , Kruse J.P. FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction. Cell Metab 2005; 2: 153–63. DOI 10.1016/j.cmet.2005.08.004

Lagouge M. , Argmann C. , Gerhart-Hines Z. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 alpha. Cell 2006; 127: 1109–22. DOI 10.1016/j.cell.2006.11.013

Rodgers J.T. , Lerin C. , Haas W. , Gygi S.P. , Spiegelman B.M. , Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1 alpha and SIRT1. Nature 2005; 434: 113–8. DOI 10.1038/nature03354

Renaud S. , Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992; 339: 1523–6.

Vingtdeux V. , Dreses-Werringloer U. , Zhao H. Therapeutic potential of resveratrol in Alzheimer's disease. BMC Neurosci 2008; 9(suppl 2): S6. DOI 10.1186/1471-2202-9-S2-S6

Feige J.N. , Lagouge M. , Canto C. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab 2008; 8: 347–58. DOI 10.1016/j.cmet.2008.08.017

Hambrock A. , de Oliveira Franz C.B. , Hiller S. Resveratrol binds to the sulfonylurea receptor (SUR) and induces apoptosis in a SUR subtype-specific manner. J Biol Chem 2007; 282: 3347–56. DOI 10.1074/jbc.M608216200

Ramsey K.M. , Mills K.F. , Satoh A. Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice. Aging Cell 2008; 7: 78–88. DOI 10.1111/j.1474-9726.2007.00355.x

Bordone L. , Motta M.C. , Picard F. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol 2006; 4: e31. Erratum in: PLoS Biol 2006; 4: e295. DOI 10.1371/journal.pbio.0040031

Rodgers J.T. , Puigserver P. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc Natl Acad Sci USA 2007; 104: 12861–6. DOI 10.1073/pnas.0702509104

Ahmed N. Advanced glycation endproducts–role in pathology of diabetic complications. Diabetes Res Clin Pract 2005; 67: 3–21. DOI 10.1016/j.diabres.2004.09.004

Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813–20. DOI 10.1038/414813a

Kumar A. , Kaundal R.K. , Iyer S. Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy. Life Sci 2007; 80: 1236–44. DOI 10.1016/j.lfs.2006.12.036

Venkatesan B. , Ghosh-Choudhury N. , Das F. Resveratrol inhibits PDGF receptor mitogenic signaling in mesangial cells: role of PTP1B. FASEB J 2008; 22: 3469–82. DOI 10.1096/fj.08-109488

Szewczuk L.M. , Forti L. , Stivala L.A. , Penning T.M. . Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J Biol Chem 2004; 279: 22727–37. DOI 10.1074/jbc.M314302200

Olas B. , Wachowicz B. , Holmsen H. Resveratrol inhibits polyphosphoinositide metabolism in activated platelets. Biochim Biophys Acta 2005; 1714: 125–33. DOI 10.1016/j.bbamem.2005.06.008

Stef G. , Csiszar A. , Lerea K. Resveratrol inhibits aggregation of platelets from high-risk cardiac patients with aspirin resistance. J Cardiovasc Pharmacol 2006; 48: 1–5. DOI 10.1097/01.fjc.0000238592.67191.ab

Lin K.H. , Hsiao G. , Shih C.M. Mechanisms of resveratrol-induced platelet apoptosis. Cardiovasc Res 2009; 83: 575–85. DOI 10.1093/cvr/cvp139

Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999; 340: 115–26.

Zou J. , Huang Y. , Chen Q. Effects of resveratrol on oxidative modification of human low density lipoprotein. Chin Med J (Engl) 2000; 113: 99–102.

Zhang H. , Zhang J. , Ungvari Z. Resveratrol improves endothelial function. Role of TNF{alpha} and vascular oxidative stress. Arterioscler Thromb Vasc Biol 2009; 29: 1164–71. DOI 10.1161/ATVBAHA.109.187146

Alcendor R.R. , Gao S. , Zhai P. Sirtl regulates aging and resistance to oxidative stress in the heart. Circ Res 2007; 100: 1512–21. DOI 10.1161/01.RES.0000267723.65696.4a

Piver B. , Berthou F. , Dreano Y. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett 2001; 125: 83–91. DOI 10.1016/S0378-4274(01)00418-0

Goldberg D.M. , Yan J. , Soleas G.J. . Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 2003; 36: 79–87. DOI 10.1016/S0009-9120(02)00397-1

Washington University School of Medicine; DSM Nutritional Products, Inc. Effect of Resvida, a comparison with calorie restriction regimen. Bethesda, MD: National Library of Medicine. www.clinicaltrials.gov/ct2/show/NCT00823381 (accessed 2009 Dec 14).

University of California, San Francisco. Mechanisms of Metabolic Regulation of Resveratrol on Humans With Metabolic Syndrome (RSV). Bethesda, MD: National Library of Medicine. www.clinicaltrials.gov/ct2/show/NCT00654667 (accessed 2009 Dec 14).

Sirtris Pharmaceuticals. Sirtuin pipeline. www.sirtrispharma.com/pipeline.html (accessed 2009 Dec 13).

Hoggard N. , Mercer J.G. , Rayner D.V. Localization of leptin receptor mRNA splice variants in murine peripheral tissues by RT-PCR and in situ hybridisation. Biochem Biophys Res Commun 1997; 232: 3–7.

Spicer L.J. , Francisco C.C. . The adipose obese gene product, leptin: evidence of direct inhibitory role in ovarian function. Endocrinology 1997; 138: 3374–9.

Bado A. , Levasseur S. , Attoub S. The stomach is a source of leptin. Nature 1998; 394: 790–3.

Friedman J.M. , Zhang Y. , Proenca R. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425–32.

Ahima R.S. , Prabakaran D. , Mantzoros C. Role of leptin in the neuroendocrine response to fasting. Nature 1996; 382: 250–2.

Marciniak S.J. , Ron D. Endoplasmic reticulum stress signaling indisease. Physiol Rev 2006; 86: 1133–49.

Ozcan U. , Cao Q. , Yilmaz E. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306: 457–61.

Ozcan U. , Yilmaz E. , Ozcan L. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006; 313: 1137–40.

Zelissen P.M. , Stenlof K. , Lean M.E. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. Diabetes Obes Metab 2005; 7: 755–61.

Ozcan L. , Ergin A.S. , Lu A. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metabolism 2009; 9: 35–51.